Engaging with social media platforms can provide real-time insights and diverse perspectives on the obesity medicines market. Here are some notable discussions:
Twitter (X):
- JAMA (@JAMA_current): Highlighted the rapid growth of GLP-1s in the compounding market due to supply shortages and expanding indications. Twitter
- Chamath Palihapitiya (@chamath): Commented on Amgen’s clinical trial data, noting the dominant positions of Eli Lilly and Novo Nordisk in the obesity drug market. Twitter
- Shares Magazine (@SHARESmag): Discussed the evolution of the obesity drug market, anticipating the introduction of daily oral tablets by 2026. Twitter
To stay informed about the latest developments in the obesity medicines market, consider the following sources:
- Ozmosi: Provides in-depth analyses of the GLP-1 agonists market, focusing on obesity treatments from leading pharmaceutical companies. Ozmosi
- IQVIA: Offers insights into market dynamics and projections, including discussions on the emergence of new markets for effective prescription medications targeting obesity. IQVIA
- Obesity Medicine Association: Features comprehensive guides on FDA-approved weight loss medications, including safety, dosage, and efficacy information. Obesity Medicine Association
- Health Advances: Analyzes the market access landscape for obesity drugs, providing expectations on payer views and coverage evolution over the next five years. Health Advances
- Fortune Business Insights: Publishes reports on the anti-obesity drugs market size and share, offering forecasts and growth trends. Fortune Business Insights
Market News
- Rybelsus Found to Significantly Reduce Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes, Cardiovascular Diseaseby OncLive articles on April 1, 2025
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 diabetes and cardiovascular disease and/or chronic kidney disease.
- Magazine: Are European biopharma manufacturers ‘nearshoring’?by Ross Law (Pharmaceutical Technology) on April 1, 2025
Is ‘nearshoring’, the preference among pharma and biotech to move operations to the domestic markets versus outsourcing abroad, becoming the norm?
- Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placementby OncLive articles on April 1, 2025
The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
- CNS market resurgence: a decade-long slump ends with $80bn milestoneby GlobalData Healthcare (Pharmaceutical Technology) on April 1, 2025
In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround.
- HHS begins layoffs in chaotic fashionby Rebecca Pifer (BioPharma Dive – Latest News) on April 1, 2025
Reduction-in-force notices went out Tuesday morning to employees across HHS. At FDA, OND director Peter Stein is departing as cuts hit CDER.
- Judge rejects J&J’s $9bn talc settlement for third timeby Jenna Philpott (Pharmaceutical Technology) on April 1, 2025
A federal judge in Houston has rejected the third attempt by J&J subsidiary Red River to settle lawsuits related to its talc-based products.
- Reshoring efforts in US FMCG business begins, but cost increases are likelyby GlobalData (Pharmaceutical Technology) on April 1, 2025
US-based Johnson & Johnson (J&J) has announced that it will be investing $55bn in new US manufacturing facilities over the next four years.
- Judge overturns FDA’s lab developed test regulation, siding with industryby Susan Kelly (BioPharma Dive – Latest News) on April 1, 2025
A Texas judge vacated the FDA’s final rule, which was strongly opposed by the laboratory industry, and remanded the matter to HHS Secretary Robert F. Kennedy Jr.
- Platform trials: The challenges, benefits, and best practices to maximize results with an EDC platformby Alexander Love (Pharmaceutical Technology) on April 1, 2025
Platform trials offer increased flexibility and reduced costs for sponsors and CROs in clinical studies.
- BioVersys secures patent claims in China for BV100by gullapalli (Pharmaceutical Technology) on April 1, 2025
BioVersys has announced the grant of key patent claims in China for the BV100 technology, the intravenous formulation of rifabutin.
- FDA approves Bavarian Nordic’s freeze-dried mpox and smallpox vaccineby Robert Barrie (Pharmaceutical Technology) on April 1, 2025
The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine reserves.
- How will AI shape the future of the NHS?by Nikki Thompson (Pharmaceutical Technology) on April 1, 2025
- Large pharma drug licensing from China hits high at 28% in 2024by GlobalData Healthcare (Pharmaceutical Technology) on April 1, 2025
Total deal value of innovator drug licensing agreements involving Chinese biopharma licensors has risen 66% to $41.5 billion in 2024.
- RNA editing biotech Airna adds $155M in fundingby Gwendolyn Wu (BioPharma Dive – Latest News) on April 1, 2025
Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a disease targeted by several other firms.
- Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSKby Jenna Philpott (Pharmaceutical Technology) on April 1, 2025
Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease caused by RSV.
- Balancing Cost-Efficiency with the Need for Domestic Manufacturingby OncLive articles on April 1, 2025
Marcel Botha, CEO of 10XBeta, discusses finding a balance between the need for cost-efficiency and the need to build domestic manufacturing capacity for essential medical devices.
- Eli Lilly Adds Alzheimer’s Care to Digital Health Platform Servicesby OncLive articles on April 1, 2025
LillyDirect will help provide services to millions of patients who have yet to be formally diagnosed with the disease.
- Pharma Pulse 4/1/25: Addressing Regulatory Challenges with Trial Diversity, Medicaid Cuts Remain Center Stage & moreby OncLive articles on April 1, 2025
The latest news for pharma industry insiders.
- Beyond the Prescription: The Role Pharma Plays in Digital Health Conversationsby OncLive articles on April 1, 2025
As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective […]
- Beyond the Prescription: Pharma’s Role in Digital Health Conversationsby OncLive articles on April 1, 2025
Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate […]
